The Pharma Data

DECEMBER 8, 2020

In August, the company reported the vaccine candidate triggered antibody-based immune responses in early and mid-stage trials. The virus was cultivated in a qualified Vero cell line for propagation, and the supernatant of the infected cells was inactivated with ? The vaccine was also demonstrating a strong safety profile.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. Early tests showed the jab, developed by US biotechnology company Novavax, leads to high levels of virus-fighting antibodies being produced. The UK government has already ordered 60 million doses in case it proves successful.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

JANUARY 22, 2021

Still, Sir Patrick Vallance, the British government’s chief scientific adviser, described the data so far as “not yet strong.” He noted that the data suggest that among 1,000 men in England aged 60 or older, the original virus would kill 10, while the new variant would kill 13 or 14, the Post reported.

Vaccine 52

Vaccine Virus Immune Response Government 52

The Pharma Data

DECEMBER 22, 2020

” Sala noted that “the time frame of the variant’s [spread] depends entirely on human behavior, including government-imposed travel restrictions.” “But again, the low mutation rate makes the adaptation of this virus to a vaccine less likely.” It has already been detected in other countries.”

Virus 52

Virus Vaccine Immune Response Treatment 52

The Pharma Data

AUGUST 28, 2020

The government plans to train up an army of health professionals to be ready to give the coronavirus vaccine, if and when one is shown to work. Oxford coronavirus vaccine triggers immune response. UK signs deals for 90 million virus vaccine doses. Image copyright. Getty Images.

Vaccine 52

Vaccine Immune Response Nurses Government 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

MARCH 29, 2022

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “The EU approval represents an important milestone in our efforts to help prevent COVID-19, and we will continue to work with governments across Europe to make Evusheld available as quickly as possible. Christoph D.

Vaccine 52

Vaccine Virus Immune Response Government 52

The Pharma Data

MARCH 25, 2022

Evusheld has the potential to provide long-lasting protection to vulnerable populations such as the immunocompromised who can’t mount an adequate response to a COVID-19 vaccine, and we’ll continue to work with governments in Europe to make Evusheld available as quickly as possible.”

Vaccine 52

Vaccine Virus Immune Response Government 52

The Pharma Data

NOVEMBER 9, 2020

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. government.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. government in order to accelerate its development and manufacturing. Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. The test targets antibodies against the spike protein.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

MARCH 25, 2021

TAK-003 is Being Studied for the Prevention of Dengue Due to any Dengue Virus Serotype in Individuals Ages Four to 60. Dengue outbreaks, which result in half a million hospitalizations globally each year, can overwhelm communities and governments because of the broad impact on the health care system. 4,5 Efficacy varied by serotype.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

JANUARY 22, 2021

Patrick Soon-Shiong MD, chairman and CEO of ImmunityBio, said: “There is an urgent need for a vaccine that not only offers immediate protection but also activates T cells to clear the virus. When multiple mutations occur at the receptor-binding domain of the spike protein, it renders antibodies ineffective.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

NOVEMBER 30, 2020

government to meet its Operation Warp Speed goals to expedite the delivery of millions of doses of safe, effective vaccines for COVID-19. About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. Novavax was awarded $1.6

Clinical Development 52

Clinical Development Vaccine Clinical Trials Immune Response 52

The Pharma Data

MARCH 16, 2021

The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission. Among them, mutations E484K, N501Y and del 69-70 are located in the spike protein, the region that enables the virus to attach to and enter the human cell. 2,3 Another variant, B.1.351,

Laboratories 52

Laboratories Clinical Trials Virus Vaccine 52

The Pharma Data

MAY 17, 2021

response in the over-50s, the age group deemed at higher risk for contracting the severe form of the virus. . The interim results from the phase 2 trial on the vaccine, published today, on the contrary, showed a “ strong neutralizing antibody response” ? Phase 2 study ?. First results are expected in the third quarter of 2021.

Immune Response 52

Immune Response Vaccine RNA Trials 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., government, Regeneron is producing approximately 300,000 doses (2,400 mg) for outpatient use under the EUA. government regarding additional doses. . futility analysis). . In the U.S.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

JANUARY 24, 2021

In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. government to advance the manufacturing and initial distribution of MK-7110 ( link ).

Vaccine 52

Vaccine Immune Response Virus Production 52

The Pharma Data

NOVEMBER 18, 2020

Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing.

Immune Response 40

Immune Response FDA Regulations Production 40

The Pharma Data

JANUARY 11, 2021

Upon binding, the antibodies block the spike protein from interacting with ACE2 and thereby prevent virus-induced cell-killing, also known as cytopathic effect. AvantGen’s partners include pharmaceutical, biotech, diagnostic and government entities, many of which are repeat customers. For more information, visit www.avantgen.com.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

SEPTEMBER 9, 2020

During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response. BNT162b2 encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S), which is the target of virus neutralizing antibodies. and Germany as well as animal immunogenicity studies.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

JUNE 24, 2021

This is a meaningful moment for adolescents, parents and entire families who are seeking protection from this virus and a return to normalcy,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “We “Making vaccines available to adolescents will help re-open schools, and support the return to a normal day-to-day life.”.

Vaccine 52

Vaccine Clinical Trials FDA Trials 52

The Pharma Data

DECEMBER 17, 2020

About casirivimab and imdevimab Casirivimab and imdevimab (formerly known as REGN-COV2 or REGEN-COV2) is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

JANUARY 22, 2021

Additional directives will foster research into new treatments for COVID-19, strengthen the collection and analysis of data to shape the government’s pandemic strategy; and direct the federal occupational safety agency to release and enforce guidelines to protect workers from getting infected, the Post reported. .

Vaccine 52

Vaccine Immune Response Packaging Disease 52

The Pharma Data

JULY 21, 2021

The companies are firmly committed to working towards equitable and affordable access for COVID-19 vaccines for all people around the world, actively working with global governments as well as global health partners with the aim to provide 2 billion doses to low and middle income countries in 2021 and 2022 – 1 billion each year.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 6, 2021

Under the MoU framework, NOCs and their local governments are expected to coordinate the administration of vaccinations to eligible Games participants. Doses provided under this MoU would be in addition to doses provided under supply agreements with governments worldwide.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

OCTOBER 22, 2020

The same virus has also been detected in sewage in Cairo, Egypt but with no evidence of local circulation. Routine immunization particularly outreach services was the area most frequently reported as disrupted. . Since the last meeting, exportation of WPV1 from Pakistan to Afghanistan has been documented. .

Vaccine 52

Vaccine International Immune Response Virus 52

The Pharma Data

MAY 7, 2021

Government,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “We Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

MARCH 3, 2022

If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness. Pfizer Inc.

Virus 52

Virus Vaccine Clinical Trials FDA 52

The Pharma Data

DECEMBER 11, 2020

Government to supply doses in 2020 & 2021. The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. immediately. Germany, Turkey, South Africa, Brazil and Argentina.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

OCTOBER 14, 2020

“While there are a number of vaccine candidates in development, we believe most are limited by their sole focus on antibody responses to the monovalent spike protein, which may be insufficient to activate the full potential of the immune system to fight the coronavirus,” said Dr. Patrick Soon-Shiong, Chairman and CEO of ImmunityBio. “By

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

PLOS: DNA Science

MAY 16, 2024

A Novel Virus Appears In retrospect, everything unfolded with astonishing speed. Did it there either recombine with another virus on its own, or inspire a manipulation of another virus of a key part of the spike gene, seeding the pandemic through a “lab leak?” Work on vaccines ensued too.

Virus 82

Virus DNA RNA Laboratories 82

The Pharma Data

AUGUST 20, 2020

T cell immune responses elicited by BNT162b2 are being evaluated in the German study and the companies expect to submit the data for peer review and potential publication. trial and we look forward to sharing T cell immune response data from the German trial in the near future.”. This press release features multimedia.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

Drug Discovery World

OCTOBER 12, 2022

It is therefore not easy to predict which structures will be synthesised in cellular processes, as their formation is not governed by sequential templates – as is the case with nucleic acids or proteins – but rather by the array of glycoenzymes present in the cell and the environmental conditions of culture. Drug Discov.

Virus 130

Virus Immune Response Production Therapies 130

The Pharma Data

DECEMBER 10, 2020

The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. The study also will explore prevention of infection by SARS-CoV-2, the virus that causes COVID-19.

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Yancopoulos, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52